POSITIVE PHASE 1 DATA REPORTED IN FABRY DISEASE

PHASE 1 TRIAL UNDERWAY IN GBA-ASSOCIATED PARKINSON’S DISEASE

RECEIVED FDA APPROVAL FOR ARYMO™ ER C-II, AN EXTENDED-RELEASE MORPHINE PRODUCT FORMULATED WITH ABUSE-DETERRENT PROPERTIES

FOR TREATMENT OF CHRONIC PAIN

PHASE 2 TRIAL FOR STEM CELL EXPANSION IN PROGRESS

THREE ACTIVE CLINICAL PROGRAMS IN PROCESS IN PHASE 2 (FOR CTCL) AND PHASE 1 (ONCOLOGY, ISCHEMIA)

AVROBIO

LTI

EGALET

MAGENTA

MIRAGEN

READ MORE

READ MORE

READ MORE

READ MORE

READ MORE

TWO PHASE 1 TRIALS IN PROCESS FOR ANTIBIOTICS AGAINST GRAM-NEGATIVE INFECTIONS

PHASE 1/2 TRIAL UNDERWAY FOR ADVANCED SOLID TUMORS

SPERO

REPLIMUNE

READ MORE

READ MORE

MULTIPLE ACTIVE CLINICAL PROGRAMS FOR RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA

UNUM

READ MORE

R&D PROGRESS

ADVANCING INNOVATIVE, HIGH-IMPACT SCIENCE

PEOPLE

RECRUITING ALL-STAR PLAYERS TO OUR MATURING PORTFOLIO

BUSINESS DEVELOPMENT

COLLABORATING FOR SUCCESS

WWW.ATLASVENTURE.COM

ADVANCES@ATLAS

HIRING: USING YOUR TEAM TO BUILD A TEAM FROM THE TRENCHES

LIFESCIVC

LIFESCIVC

LIFESCIVC

LIFESCIVC

GETTING STRUCK TWICE: ACQUISITIONS & SPINOUTS IN BIOTECH

READ

READ

UPDATES@ATLAS

EMAIL US TO LEARN MORE

PAINFUL TRUTH: SUCCESSFUL FAILURE OF A BIOTECH STARTUP READ

FOUR DECADES OF HACKING BIOTECH AND YET BIOLOGY STILL CONSUMES EVERYTHING

READ

THE INESCAPABLE GRAVITY OF BIOTECH’S KEY CLUSTERS: THE GREAT CONSOLIDATION OF TALENT, CAPITAL, AND RETURNS

READ

THOUGHT LEADERSHIP@ATLAS

READ MORE

READ MORE

READ MORE

READ MORE

KEVIN BITTERMAN ATLAS VENTURE FUND XI CLOSES AT $350M HARD-CAP

BIG NEWS@ATLAS

FINANCINGS

POWERING UP OUR PORTFOLIO

NEW PORTFOLIO

LAUNCHING NEW BIOTECHS

PUBLIC COMPANIES

ACCESSING THE PUBLIC MARKETS

Multiple clinical stage programs advancing RNA-targeted therapies for diseases with high unmet medical need

MIRAGEN GOES PUBLIC VIA REVERSE MERGER: NASDAQ: MGEN

READ THE PRESS RELEASE

Advancing novel platform and clinical-stage pipeline for the development of Synthetic Biotic medicines to treat metabolic and inflammatory diseases and cancer

SYNLOGIC GOES PUBLIC VIA REVERSE MERGER: NASDAQ: SYBX

READ THE PRESS RELEASE

Advancing in vivo and ex vivo programs using CRISPR/Cas9 technology across a range of diseases

INTELLIA THERAPEUTICS RAISES FOLLOW-ON PUBLIC FINANCING: NASDAQ: NTLA

READ THE PRESS RELEASE

Clinical stage pipeline advancing novel treatments for multi-drug resistant bacterial infections

SPERO THERAPEUTICS GOES PUBLIC VIA IPO: NASDAQ: SPRO

READ THE PRESS RELEASE

EMERGING COMPANY ANALYST DAY ATLAS IPO BOOTCAMP

Emerging Atlas portfolio companies engage with a curated group of biotech analysts

Industry experts lead a seminar on IPO process and life as a public company

ATLAS AROUND THE ECOSYSTEM

Jason Rhodes speaks at the 2017 Capital W Boston Women’s Venture Summit

Kevin Bitterman judges BioPharm America’s start-up competition and speaks at Fierce Biotech’s Drug Development Forum

Peter Barrett becomes chair of Harvard Business School’s Blavatnik Fellowship in Life Sciences

David Grayzel, member of One Brave Idea, helps formally open OBI’s Science Innovation Center in Boston

ATLAS PORTFOLIO CAREERS

SUBMIT YOUR RESUME TODAY

Our portfolio companies are looking for their next great hire

CAREERS

M&A

NEW PARTNER NEW FUND

BMS ACQUIRES CELGENE ACQUIRESONCOLOGY PIPELINE DELINIA $2.3B $775MFOR UP TO FOR UP TO

RANA THERAPEUTICS RELAUNCHES AS TRANSLATE BIOLEARN MORE

CELGENE PURCHASES OPTIONS TO ACQUIRE NIMBUS’ TYK2 AND STING PROGRAMSLEARN MORE

BICYCLE AND BIOVERATIV ENTER RESEARCH COLLABORATION WORTH UP TO $425MLEARN MORE

F-STAR AND MERCK ENTER STRATEGIC COLLABORATION WORTH UP TO €115M OVER TWO YEARSLEARN MORE

LTI STRIKES OPTION M&A DEAL WITH ALLERGANLEARN MORE

BICYCLE THERAPEUTICS RAISES

RODIN THERAPEUTICS RAISES

MAGENTA THERAPEUTICS RAISES

REPLIMUNE RAISES

£40M Series B $50M Series B

$55M Series B $27M Series B

CLICK EACH LOGO TO LEARN MORE

CLICK EACH NAME TO LEARN MORE

CLICK EACH LOGO TO LEARN MORE

CLICK EACH LOGO TO LEARN MORE

LAUNCHES WITH

TO TREAT PATIENTS WITH NEUROLOGICAL DISEASES

LED BY

LED BY

LED BY LED BY

LED BY

LED BY

$30M Series ALAUNCHES WITH

TO DEVELOP PRECISION MEDICINES FOR AMD & GENETIC DISEASES

TO ADVANCE TITRATABLE, RE-DOSABLE, SCALABLE GENETIC MEDICINES

LAUNCHES TODAY WITH

$42.5M Series A

$25M Series ALAUNCHES WITH

TO TARGET “UNDRUGGABLE” DISEASE PATHWAYS

$30M Series A

LAUNCHES WITH

TO ADVANCE A NOVEL APPROACH TO TREAT CANCER

$49M Series ALAUNCHES WITH

TO DEVELOP A NEW CLASS OF CELL AND GENE THERAPIES

$49.5M Series A

MICHAEL CURTIS

CADENTPRESIDENT & CEO

KATINA DORTON

AVROBIOCFO

ANDREW GENGOS

SYNLOGICCOO

JEFF HATFIELD

ZAFGENCEO

ANN BARBIER

TRANSLATECMO

HOWARD KAUFMAN

REPLIMUNECMO

MARTIN SEIDEL

IFM THERAPEUTICSEVP OF R&D

MICHAEL HEARTLEIN

TRANSLATECTO

LEE KALOWSKI

BICYCLECFO

, CSORaj Devraj, CBOPeter Keller , CTOScott Lauder

, President & CEOJames McLaughlin

Doug Kerr, Head of Preclinical Research and Clinical Development

, President & CEOGeoff McDonough

, CFOGlenn Goddard

, COOMark Angelino, Head of DiscoveryRobert Kotin

, Head of Platform ResearchMatt Stanton

, President & CEOLaurent Audoly, CTONello Mainolfi

, CEOMichael Gilman, SVP, Head of Business OperationsTariq Kassum

, SVP, Head of ResearchSteve Shamah

, President & CEOMark Manfredi